<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01053390</url>
  </required_header>
  <id_info>
    <org_study_id>xh2009-35</org_study_id>
    <nct_id>NCT01053390</nct_id>
  </id_info>
  <brief_title>New Chemotherapy Regimen in the Treatment of Advanced Gallbladder Carcinoma</brief_title>
  <official_title>A Phase III Study of New Chemotherapy Regimen in the Treatment of Advanced Gallbladder Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Xuanwu Hospital, Beijing</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Capital Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking University First Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tianjin Medical University Cancer Institute and Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Dalian Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>China Medical University, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The first clinical college of harbin medical university</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Second Affiliated Hospital of Harbin Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shengjing Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jilin University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The people’s hospital of Heilongjiang province</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eastern Hepatobiliary Surgery Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Changzheng Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shandong Provincial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Qilu Hospital of Shandong University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fourth Military Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tang-Du Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Qinghai People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Affiliated Hospital of Qinghai University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital of Chongqing Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Daping Hospital and the Research Institute of Surgery of the Third Military Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First People's Hospital of Kunming</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>LanZhou University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xi'an Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The first people’s hospital of Guiyang</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Southwest Hospital, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Kunming Medical College</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Jiao Tong University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective Primary:

      Determine the objective response rate in patients with advanced gallbladder treated with new
      Chemotherapy regimen

      Secondary:

      Determine time to progression-free survival and overall survival of patients treated with
      this regimen.

      Determine quality of life of patients treated with this regimen. Determine the toxicity of
      new chemotherapy regimen
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Design: Treatment, Randomized, Open Label, controlled,Multicenter Group Assignment,
      Safety/Efficacy Study

      Chemotherapy regimen:

      Group A: Conventional chemotherapy regimen Group B: New chemotherapy regimen: conventional
      regimen plus SST（somatostatin） Cycles repeat every 4 weeks and 6 cycles in total

      Patients: A total of 260 patients (130 per group) will be accrued for this study.

      Patients distribution:

      10patients per center are enrolled in the study and 30 centers (hospitals) in total which
      meet the total number of patients in trial.

      Clinical Outcome Assessments:

      Primary: the objective response rate (response evaluation criteria in solid tumors ,RECIST
      criteria) Secondary: progression-free survival, overall survival, quality of life，the adverse
      event

      Safety Assessments:

      Physical exam, laboratory test, probably occurred adverse event.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>(Response Evaluation Criteria in Solid Tumors, RECIST,2009 ), CR(complete response) and PR(partial response)</measure>
    <time_frame>6 month after first treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>A: KPS (karnofsky performance score) B:Laboratory tests: Reexamination of CA19-9（Carbohydrate Antigen 19-9）、 CEA（ carcinoembryonic antigen）, especially for those which are abnormal prior to chemotherapy</measure>
    <time_frame>6 month after first treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">216</enrollment>
  <condition>Gallbladder Neoplasms</condition>
  <arm_group>
    <arm_group_label>epirubicin,cisplatin,LV（Leucovorin）、5-FU (5-Fluorouracil)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>conventional regimen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Somatotatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Conventional chemotherapy regimen plus somatostatin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Somatostatin</intervention_name>
    <description>Somatostatin 3mg+NS（normal saline）60ml, a continuous intravenous infusion, q12h</description>
    <arm_group_label>Somatotatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>epirubicin, cisplatin, LV（Leucovorin）、 5-FU（5-Fluorouracil）</intervention_name>
    <arm_group_label>epirubicin,cisplatin,LV（Leucovorin）、5-FU (5-Fluorouracil)</arm_group_label>
    <arm_group_label>Somatotatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with unresectable locally advanced disease or unresectable local recurrence,
             including:

               -  Patients with unresectable advanced gallbladder cancer （≥ Nevin staging IV or
                  TNM（ tumor node metastasis） classification）

               -  Patients with complication who have no indication for surgery

               -  Patients with unresectable local recurrence lesions

          2. Age between 18-75, no gender-based constraints

          3. Estimated life expectancy ≥12 weeks

          4. KPS（Karnofsky performance status ）≥60

          5. Each patient gave written informed consent

          6. &lt; 2 previous chemotherapy regimes

          7. No chemotherapy done in the last 4 weeks

          8. Laboratory test criteria:Haemoglobin ≥ 10g/dl, white blood cell count &gt; 3,000/mm3
             ;Platelet &gt;100,000/mm3 Total bilirubin &lt;5.0mg/dl ALT（alanine transaminase）、
             AST（aspartate aminotransferase)≤ 2.5 times upper limit of normal BUN（blood urea
             nitrogen）≤ 2 times upper limit of normal; serum creatinine &lt;1.5mg/dl: creatinine
             clearance rate &lt; 60 ml/min

          9. Patients are required to have histologically confirmed diagnosis via puncture based at
             least on computed tomography (CT) or ultrasound

         10. Jaundice should be reduced to standard level before chemotherapy (Total bilirubin &lt;5.0
             mg/dl)

        Exclusion Criteria:

          1. Patients with extensive metastasis and generally poor condition who can not tolerate
             chemotherapy

          2. Patients who are pregnant or breastfeeding.

          3. Patients with other clinically significant laboratory abnormalities, uncontrolled
             infection, concurrent severe medical problems unrelated to malignancy

          4. Patients who had a history of previous carcinoma in the last 5 years.

          5. Patients who are allergic to somatostatin or fluorouracil

          6. Patients who refuse chemotherapy, or to sign the informed consent and chemotherapy
             consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhi-wei Quan, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Xinhua hospital affiliated shanghai jiaotong university school of medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Xinhua hospital affiliated shanghai jiaotong</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://www.btcrc.com.cn</url>
  </link>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 20, 2010</study_first_submitted>
  <study_first_submitted_qc>January 20, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 21, 2010</study_first_posted>
  <last_update_submitted>December 18, 2013</last_update_submitted>
  <last_update_submitted_qc>December 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 20, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Jiao Tong University School of Medicine</investigator_affiliation>
    <investigator_full_name>Zhi-wei Quan</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>gallbladder neoplasmas</keyword>
  <keyword>Gallbladder Neoplasms,Advanced Stage,Chemotherapy,Somatostatin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gallbladder Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
    <mesh_term>Somatostatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

